Virus–Receptor Interactions: Structural Insights For Oncolytic Virus Development

References

• Peters C, Grandi P, Nigim F. Updates on oncolytic virus immunotherapy for cancers. Mol Ther Oncolytics. 2019;12:259–262. doi:10.1016/j.omto.2019.01.008
   PubMed Web of Science ®Google Scholar
• Geletneky K, Hajda J, Angelova AL, et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/Iia glioblastoma trial. Mol Ther. 2017;25(12):2620–2634. doi:10.1016/j.ymthe.2017.08.01628967558
   PubMed Web of Science ®Google Scholar
• Aref S, Bailey K, Fielding A. Measles to the rescue: a review of oncolytic measles virus. Viruses. 2016;8(10):294.
   PubMed Web of Science ®Google Scholar
• Lazar I, Yaacov B, Shiloach T, et al. The oncolytic activity of newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein livin. J Virol. 2010;84(1):639.19864394
   PubMed Web of Science ®Google Scholar
• Hiley CT, Yuan M, Lemoine NR, Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 2009;17:281.19890355
   PubMed Web of Science ®Google Scholar
• McCarthy C, Jayawardena N, Burga LN, Bostina M. Developing picornaviruses for cancer therapy. Cancers. 2019;11:5.
   Web of Science ®Google Scholar
• Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839–846.29420123
   PubMed Web of Science ®Google Scholar
• Holl EK, Brown MC, Boczkowski D, et al. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget. 2016;7(48):79828–79841.27806313
   PubMedGoogle Scholar
• Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60:6359–66.11103798
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642. doi:10.1038/nrd466326323545
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, De Silva NS, Falls TJ, et al. Targeting tumor vasculature with an oncolytic virus. Mol Ther. 2011;19(5):886–894. doi:10.1038/mt.2011.2621364541
   PubMed Web of Science ®Google Scholar
• Vähä-Koskela M, Hinkkanen A. Tumor restrictions to oncolytic virus. Biomedicines. 2014;2(2):163–194. doi:10.3390/biomedicines202016328548066
   PubMedGoogle Scholar
• Filley AC, Dey M. Immune system, friend or foe of oncolytic virotherapy? Front Oncol. 2017;7:106. doi:10.3389/fonc.2017.0010628589085
   PubMed Web of Science ®Google Scholar
• Anderson DB, Laquerre S, Ghosh K, et al. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein g enables mutant virus attachment and entry. J Virol. 2000;74(16):7698. doi:10.1128/JVI.74.16.7698-7698.2000
   Web of Science ®Google Scholar
• Ilett EJ, Bárcena M, Errington-Mais F, et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res. 2011;17(9):2767. doi:10.1158/1078-0432.CCR-10-326621389099
   PubMed Web of Science ®Google Scholar
• Boonstra MC, de Geus SWL, Prevoo HAJM, et al. Selecting targets for tumor imaging: an overview of cancer-associated membrane proteins. Biomark Cancer. 2016;8:119–133. doi:10.4137/BIC.S3854227721658
   PubMedGoogle Scholar
• Pellet PE and Roizman B. The family herpesviridae: a brief introduction. In: Knipe DM and Howley PM, editors. In Fields Virology. Philadelphia [PA]: Lippincott Williams & Wilkins; 2007:2479–2499
   Google Scholar
• Yuan S, Wang J, Zhu D, et al. Cryo-EM structure of a herpesvirus capsid at 3.1 Å. Science. 2018;360(6384):eaao7283. doi:10.1126/science.aao728329622627
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513–1518. doi:10.1016/S0140-6736(00)04638-911377626
   PubMed Web of Science ®Google Scholar
• Greig SL. Talimogene laherparepvec: first global approval. Drugs. 2016;76(1):147–154. doi:10.1007/s40265-015-0522-726620366
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio FA, Amatruda T, et al. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). J Immunother Cancer. 2014;2(3):P263.
   Google Scholar
• Andtbacka RHI, Curti B, Hallmeyer S, et al. Phase II CALM extension study: enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21. Eur J Cancer. 2015;51:S677–S677.
   Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.26014293
   PubMed Web of Science ®Google Scholar
• O’Donoghue C, Doepker MP, Zager JS. Talimogene laherparepvec: overview, combination therapy and current practices. Melanoma Manage. 2016;3(4):267–272.
   Google Scholar
• Senior M. Checkpoint inhibitors go viral. Nat Biotechnol. 2019;37:12.30605149
   PubMed Web of Science ®Google Scholar
• Markert JM, Razdan SN, Kuo H-C, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014;22(5):1048–1055.24572293
   PubMed Web of Science ®Google Scholar
• Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010;21(9):1119–1128.20486770
   PubMed Web of Science ®Google Scholar
• Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest. 2001;108(4):503–510.11518721
   PubMed Web of Science ®Google Scholar
• Agelidis AM, Shukla D. Cell entry mechanisms of HSV: what we have learned in recent years. Future Virol. 2015;10(10):1145–1154.27066105
   PubMed Web of Science ®Google Scholar
• Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003;16(1):96.12525427
   PubMed Web of Science ®Google Scholar
• Di Giovine P, Settembre EC, Bhargava AK, et al. Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog. 2011;7(9):e1002277.21980294
   PubMed Web of Science ®Google Scholar
• Zhang N, Yan J, Lu G, et al. Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion. Nat Commun. 2011;2:577.22146396
   PubMed Web of Science ®Google Scholar
• Carfí A, Willis SH, Whitbeck JC, et al. Herpes simplex virus glycoprotein d bound to the human receptor HveA. Mol Cell. 2001;8(1):169–179.11511370
   PubMed Web of Science ®Google Scholar
• Kuroki K, Wang J, Ose T, et al. Structural basis for simultaneous recognition of an O-glycan and its attached peptide of mucin family by immune receptor PILRα. Proc Natl Acad Sci. 2014;111(24):8877.24889612
   PubMed Web of Science ®Google Scholar
• Pasdeloup D, Blondel D, Isidro AL, Rixon FJ. Herpesvirus capsid association with the nuclear pore complex and viral DNA release involve the nucleoporin CAN/Nup214 and the capsid protein pUL25. J Virol. 2009;83(13):6610–6623.19386703
   PubMed Web of Science ®Google Scholar
• Malissen N, Macagno N, Granjeaud S, et al. HVEM: A novel cosignaling molecule of major interest in melanoma. J Clin Oncol. 2017;35(15_suppl):e14591–e14591.
   Web of Science ®Google Scholar
• Hokuto D, Sho M, Yamato I, et al. Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma. Eur J Cancer. 2015;51(2):157–165.25468715
   PubMed Web of Science ®Google Scholar
• Lan X, Li S, Gao H, et al. Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis. Onco Targets Ther. 2017;10:919–926.28243127
   PubMed Web of Science ®Google Scholar
• Spear PG, Eisenberg RJ, Cohen GH. Three classes of cell surface receptors for alphaherpesvirus entry. Virology. 2000;275(1):1–8.11017782
   PubMed Web of Science ®Google Scholar
• Ogita H, Takai Y. Nectins and nectin-like molecules: roles in cell adhesion, polarization, movement, and proliferation. IUBMB Life. 2006;58(5‐6):334–343.16754328
   PubMed Web of Science ®Google Scholar
• Martin TA, Lane J, Harrison GM, Jiang WG. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS One. 2013;8(12):e82696–e82696.24386110
   PubMed Web of Science ®Google Scholar
• Yu Z, Chan M-K, O-Charoenrat P, et al. Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res. 2005;11(13):4889.16000587
   PubMed Web of Science ®Google Scholar
• Yu Z, Adusumilli PS, Eisenberg DP, et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther. 2007;15(1):103–113.17164781
   PubMed Web of Science ®Google Scholar
• Tampakis A, Tampaki EC, Nonni A, et al. Nectin-1 expression in colorectal cancer: is there a group of patients with high risk for early disease recurrence? Oncology. 2019;96(6):318–325.30917374
   PubMed Web of Science ®Google Scholar
• Cocchi F, Menotti L, Mirandola P, Lopez M, Campadelli-Fiume G. The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells. J Virol. 1998;72(12):9992–10002.9811737
   PubMed Web of Science ®Google Scholar
• Nakano K, Asano R, Tsumoto K, et al. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther. 2005;11(4):617–626.15771964
   PubMed Web of Science ®Google Scholar
• Smith GL, Murphy BJ, Law M. Vaccinia virus motility. Annu Rev Microbiol. 2003;57(1):323–342.14527282
   PubMed Web of Science ®Google Scholar
• Wilkinson L. Jenner’s smallpox vaccine. The riddle of vaccinia virus and its origin. Med Hist. 1982;26(1):94–95.
   Google Scholar
• Joklik WK, Becker Y. The replication and coating of vaccinia DNA. J Mol Biol. 1964;10(3):452–474.14255112
   PubMed Web of Science ®Google Scholar
• Chung C-S, Chen C-H, Ho M-Y, Huang C-Y, Liao C-L, Chang W. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol. 2006;80(5):2127.16474121
   PubMed Web of Science ®Google Scholar
• Ichihashi Y, Oie M. Neutralizing epitope on penetration protein of vaccinia virus. Virology. 1996;220(2):491–494.8661400
   PubMed Web of Science ®Google Scholar
• Strassburg MA. The global eradication of smallpox. Am J Infect Control. 1982;10(2):53–59.7044193
   PubMed Web of Science ®Google Scholar
• Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther. 2004;4(6):901–917.15174972
   PubMed Web of Science ®Google Scholar
• Haddad D. Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery. Front Oncol. 2017;7:96.28589082
   PubMed Web of Science ®Google Scholar
• Thorne SH, Hwang TH, Kirn DH. Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther. 2005;7(4):359–365.16121702
   PubMedGoogle Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99.21886163
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329.23396206
   PubMed Web of Science ®Google Scholar
• Townsley AC, Weisberg AS, Wagenaar TR, Moss B. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol. 2006;80(18):8899.16940502
   PubMed Web of Science ®Google Scholar
• Carter GC, Law M, Hollinshead M, Smith GL. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol. 2005;86(5):1279–1290.15831938
   PubMed Web of Science ®Google Scholar
• Belting M. Glycosaminoglycans in cancer treatment. Thromb Res. 2014;133:S95–S101.24862153
   PubMed Web of Science ®Google Scholar
• Rodriguez JF, Smith GL. IPTG-dependent vaccinia virus: identification of a virus protein enabling virion envelopment by Golgi membrane and egress. Nucleic Acids Res. 1990;18(18):5347–5351.2216706
   PubMed Web of Science ®Google Scholar
• Lin C-L, Chung C-S, Heine HG, Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol. 2000;74(7):3353.10708453
   PubMed Web of Science ®Google Scholar
• Hsiao J-C, Chung C-S, Chang W. Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain. J Virol. 1998;72(10):8374.9733888
   PubMed Web of Science ®Google Scholar
• Hsiao J-C, Chung C-S, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol. 1999;73(10):8750.10482629
   PubMed Web of Science ®Google Scholar
• Chung C-S, Hsiao J-C, Chang Y-S, Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol. 1998;72(2):1577.9445060
   PubMed Web of Science ®Google Scholar
• McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61(24):8751.11751395
   PubMed Web of Science ®Google Scholar
• Gammon DB, Gowrishankar B, Duraffour S, Andrei G, Upton C, Evans DH. Vaccinia virus–encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog. 2010;6(7):e1000984.20628573
   PubMed Web of Science ®Google Scholar
• Banerjee AK. Transcription and replication of rhabdoviruses. Microbiol Rev. 1987;51(1):66–87.3550409
   PubMedGoogle Scholar
• Leyrat C, Ribeiro EA, FCA G, Ivanov I, Ruigrok RWH, Jamin M. Structure, interactions with host cell and functions of rhabdovirus phosphoprotein. Future Virol. 2011;6(4):465–481.
   Web of Science ®Google Scholar
• Felt SA, Grdzelishvili VZ. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. J Gen Virol. 2017;98(12):2895–2911.
   PubMed Web of Science ®Google Scholar
• Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012;93(12):2529–2545.23052398
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263–275.14585354
   PubMed Web of Science ®Google Scholar
• Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci. 2013;110(18):7306.23589850
   PubMed Web of Science ®Google Scholar
• Gonias SL, Karimi-Mostowfi N, Murray SS, Mantuano E, Gilder AS. Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival. PLoS One. 2017;12(10):e0186649–e0186649.29088295
   PubMed Web of Science ®Google Scholar
• Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887–918.18626063
   PubMed Web of Science ®Google Scholar
• Nikolic J, Belot L, Raux H, et al. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat Commun. 2018;9(1):1029.29531262
   PubMed Web of Science ®Google Scholar
• Sieczkarski SB, Whittaker GR. Influenza virus can enter and infect cells in the absence of clathrin-mediated endocytosis. J Virol. 2002;76(20):10455.12239322
   PubMed Web of Science ®Google Scholar
• Sun X, Roth SL, Bialecki MA, Whittaker GR. Internalization and fusion mechanism of vesicular stomatitis virus and related rhabdoviruses. Future Virol. 2010;5(1):85–96.23516023
   PubMed Web of Science ®Google Scholar
• Le Boeuf F, Gebremeskel S, McMullen N, et al. Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models. Mol Ther Oncolytics. 2017;6:80–89.28856238
   PubMed Web of Science ®Google Scholar
• Salsman J, Top D, Boutilier J, Duncan R. Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J Virol. 2005;79(13):8090–8100.15956554
   PubMed Web of Science ®Google Scholar
• Muik A, Stubbert LJ, Jahedi RZ, et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res. 2014;74(13):3567.24812275
   PubMed Web of Science ®Google Scholar
• Smelt SC, Borrow P, Kunz S, et al. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor α-dystroglycan correlate with viral tropism and disease kinetics. J Virol. 2001;75(1):448.11119613
   PubMed Web of Science ®Google Scholar
• Kunz S, Rojek JM, Kanagawa M, et al. Posttranslational modification of α-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol. 2005;79(22):14282.16254363
   PubMed Web of Science ®Google Scholar
• Calogero A, Pavoni E, Gramaglia T, et al. Altered expression of alpha-dystroglycan subunit in human gliomas. Cancer Biol Ther. 2006;5(4):441–448.16575202
   PubMed Web of Science ®Google Scholar
• Tong JG, Valdes YR, Sivapragasam M, et al. Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential. BMC Cancer. 2017;17(1):594.28854921
   PubMed Web of Science ®Google Scholar
• Tong JG, Valdes YR, Barrett JW, et al. Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. Mol Ther Oncolytics. 2015;2:15013.27119108
   PubMed Web of Science ®Google Scholar
• Brun J, McManus D, Lefebvre C, et al. Identification of genetically modified maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010;18(8):1440–1449.20551913
   PubMed Web of Science ®Google Scholar
• Le Boeuf F, Selman M, Son HH, et al. Oncolytic maraba virus MG1 as a treatment for sarcoma. Int J Cancer. 2017;141(6):1257–1264.28568891
   PubMed Web of Science ®Google Scholar
• Pol JG, Atherton MJ, Bridle BW, et al. Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virotherapy. 2018;7: 117–128.30538968
   PubMed Web of Science ®Google Scholar
• Brown VR, Bevins SN. A review of virulent Newcastle disease viruses in the United States and the role of wild birds in viral persistence and spread. Vet Res. 2017;48(1):68.29073919
   PubMed Web of Science ®Google Scholar
• Bulbule NR. Virulence of Newcastle disease virus and diagnostic challenges. Adv Anim Vet Sci. 2015;3(5s):14–21.
   Google Scholar
• Yurchenko KS, Zhou P, Kovner AV, Zavjalov EL, Shestopalova LV, Shestopalov AM. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS One. 2018;13(4):e0195425.29621357
   PubMed Web of Science ®Google Scholar
• Buijs PRA, van Eijck CHJ, Hofland LJ, Fouchier RAM. van den Hoogen BG. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther. 2014;21:24.24384773
   PubMed Web of Science ®Google Scholar
• Lam HY, Yeap SK, Rasoli M, et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. Biomed Res Int. 2011;2011:718710.
   Google Scholar
• Fournier P, Bian H, Szeberényi J, Schirrmacher V. Analysis of three properties of newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation In: Kirn DH, Liu T-C, Thorne SH, editors. Oncolytic Viruses: Methods and Protocols. Totowa, NJ: Humana Press; 2012:177–204.
   Google Scholar
• Zaitsev V, von Itzstein M, Groves D, et al. Second sialic acid binding site in newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. J Virol. 2004;78(7):3733.15016893
   PubMed Web of Science ®Google Scholar
• Teoh ST, Ogrodzinski MP, Ross C, Hunter KW, Lunt SY. Sialic acid metabolism: a key player in breast cancer metastasis revealed by metabolomics. Front Oncol. 2018;8:174.29892572
   PubMed Web of Science ®Google Scholar
• Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann DD, Samal SK. The hemagglutinin-neuraminidase protein of newcastle disease virus determines tropism and virulence. J Virol. 2004;78(8):4176.15047833
   PubMed Web of Science ®Google Scholar
• Crennell S, Takimoto T, Portner A, Taylor G. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol. 2000;7:1068.11062565
   PubMedGoogle Scholar
• Iorio RM, Field GM, Sauvron JM, et al. Structural and functional relationship between the receptor recognition and neuraminidase activities of the newcastle disease virus hemagglutinin-neuraminidase protein: receptor recognition is dependent on neuraminidase activity. J Virol. 2001;75(4):1918. doi:10.1128/JVI.75.4.1918-1927.200111160691
   PubMed Web of Science ®Google Scholar
• Bousse TL, Taylor G, Krishnamurthy S, Portner A, Samal SK, Takimoto T. Biological significance of the second receptor binding site of newcastle disease virus hemagglutinin-neuraminidase protein. J Virol. 2004;78(23):13351. doi:10.1128/JVI.78.23.13351-13355.200415542686
   PubMed Web of Science ®Google Scholar
• Mahon PJ, Mirza AM, Iorio RM. Role of the two sialic acid binding sites on the newcastle disease virus HN protein in triggering the interaction with the F protein required for the promotion of fusion. J Virol. 2011;85(22):12079–12082. doi:10.1128/JVI.05679-1121880745
   PubMed Web of Science ®Google Scholar
• Plattet P, Alves L, Herren M, Aguilar HC. Measles virus fusion protein: structure, function and inhibition. Viruses. 2016;8(4):112. doi:10.3390/v804011227110811
   PubMed Web of Science ®Google Scholar
• Plemper RK, Hammond AL. Synergizing vaccinations with therapeutics for measles eradication. Expert Opin Drug Discov. 2014;9(2):201–214. doi:10.1517/17460441.2014.86732424303998
   PubMed Web of Science ®Google Scholar
• Gutsche I, Desfosses A, Effantin G, et al. Near-atomic cryo-EM structure of the helical measles virus nucleocapsid. Science. 2015;348(6235):704. doi:10.1126/science.aaa513925883315
   PubMed Web of Science ®Google Scholar
• Hashiguchi T, Kajikawa M, Maita N, et al. Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci. 2007;104(49):19535. doi:10.1073/pnas.070783010418003910
   PubMed Web of Science ®Google Scholar
• Hashiguchi T, Fukuda Y, Matsuoka R, et al. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors. Proc Natl Acad Sci. 2018;115(10):2496. doi:10.1073/pnas.171895711529463726
   PubMed Web of Science ®Google Scholar
• Santiago C, Celma ML, Stehle T, Casasnovas JM. Structure of the measles virus hemagglutinin bound to the CD46 receptor. Nat Struct Mol Biol. 2009;17:124. doi:10.1038/nsmb.172620010840
   PubMed Web of Science ®Google Scholar
• Hashiguchi T, Ose T, Kubota M, et al. Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. Nat Struct Mol Biol. 2011;18:135. doi:10.1038/nsmb.196921217702
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu G, Qi J, et al. Structure of measles virus hemagglutinin bound to its epithelial receptor nectin-4. Nat Struct Mol Biol. 2012;20:67. doi:10.1038/nsmb.243223202587
   PubMed Web of Science ®Google Scholar
• Anderson BD, Nakamura T, Russell SJ, Peng K-W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64(14):4919. doi:10.1158/0008-5472.CAN-04-088415256464
   PubMed Web of Science ®Google Scholar
• Nishiwada S, Sho M, Yasuda S, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34(1):30. doi:10.1186/s13046-015-0144-725888293
   PubMed Web of Science ®Google Scholar
• Tatsuo H, Ono N, Tanaka K, SLAM YY. (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893–897. doi:10.1038/3502257910972291
   PubMed Web of Science ®Google Scholar
• Russell S. CD46: A complement regulator and pathogen receptor that mediates links between innate and acquired immune function. Tissue Antigens. 2004;64(2):111–118. doi:10.1111/j.1399-0039.2004.00277.x15245366
   PubMedGoogle Scholar
• Persson BD, Reiter DM, Marttila M, et al. Adenovirus type 11 binding alters the conformation of its receptor CD46. Nat Struct Mol Biol. 2007;14:164. doi:10.1038/nsmb119017220899
   PubMed Web of Science ®Google Scholar
• Santiago C, Björling E, Stehle T, Casasnovas JM. Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein. J Biol Chem. 2002;277(35):32294–32301. doi:10.1074/jbc.M20297320012065582
   PubMed Web of Science ®Google Scholar
• Lecouturier V, Fayolle J, Caballero M, et al. Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol. 1996;70(7):4200.8676439
   PubMed Web of Science ®Google Scholar
• Zhang S-C, Wang W-L, Cai W-S, Jiang K-L, Yuan Z-W. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. BMC Cancer. 2012;12(1):427. doi:10.1186/1471-2407-12-42723009685
   PubMed Web of Science ®Google Scholar
• Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015;75(1):22. doi:10.1158/0008-5472.CAN-14-356925398436
   PubMed Web of Science ®Google Scholar
• Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010;70(3):875. doi:10.1158/0008-5472.CAN-09-276220103634
   PubMed Web of Science ®Google Scholar
• Russell SJ, Federspiel MJ, Peng K-W, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926–933. doi:10.1016/j.mayocp.2014.04.00324835528
   PubMed Web of Science ®Google Scholar
• Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol. 2004;78(1):302–313. doi:10.1128/JVI.78.1.302-313.200414671112
   PubMed Web of Science ®Google Scholar
• Nakamura T, Peng K-W, Vongpunsawad S, et al. Antibody-targeted cell fusion. Nat Biotechnol. 2004;22(3):331–336. doi:10.1038/nbt94214990955
   PubMed Web of Science ®Google Scholar
• Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23(2):209–214. doi:10.1038/nbt106015685166
   PubMed Web of Science ®Google Scholar
• Buckwalter SP, Teo R, Espy MJ, Sloan LM, Smith TF, Pritt BS. Real-time qualitative PCR for 57 human adenovirus types from multiple specimen sources. J Clin Microbiol. 2012;50(3):766. doi:10.1128/JCM.01263-1122170906
   PubMed Web of Science ®Google Scholar
• Cheng L, Huang X, Li X, et al. Cryo-EM structures of two bovine adenovirus type 3 intermediates. Virology. 2014;450–451:174–181. doi:10.1016/j.virol.2013.12.012
   PubMed Web of Science ®Google Scholar
• Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp). 2014;4(1):26–33. doi:10.1556/EuJMI.4.2014.1.224678403
   PubMedGoogle Scholar
• Yabe Y, Samper L, Bryan E, Taylor G, Trentin JJ. Oncogenic effect of human adenovirus type 12, in mice. Science. 1964;143(3601):46. doi:10.1126/science.143.3601.4614075711
   PubMed Web of Science ®Google Scholar
• Trentin JJ, Yabe Y, Taylor G. The quest for human cancer viruses. Science. 1962;137(3533):835. doi:10.1126/science.137.3530.57113922417
   PubMed Web of Science ®Google Scholar
• Niemann J, Kühnel F. Oncolytic viruses: adenoviruses. Virus Genes. 2017;53(5):700–706. doi:10.1007/s11262-017-1488-128702840
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879. doi:10.1038/7863810932224
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–1427. doi:10.1200/JCO.2017.75.821929432077
   PubMed Web of Science ®Google Scholar
• Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res. 2009;143(2):184–194. doi:10.1016/j.virusres.2009.02.01019647886
   PubMed Web of Science ®Google Scholar
• Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to many ends. Adv Drug Deliv Rev. 2007;59(8):810–821. doi:10.1016/j.addr.2007.06.00717707546
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bergelson JM. Adenovirus Receptors. J Virol. 2005;79(19):12125. doi:10.1128/JVI.79.20.12905-12913.200516160140
   PubMed Web of Science ®Google Scholar
• Chrétien I, Marcuz A, Courtet M, et al. CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur J Immunol. 1998;28(12):4094–4104. doi:10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.0.CO;2-29862345
   PubMed Web of Science ®Google Scholar
• Freimuth P, Springer K, Berard C, Hainfeld J, Bewley M, Flanagan J. Coxsackievirus and adenovirus receptor amino-terminal immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from adenovirus type 12. J Virol. 1999;73(2):1392.9882344
   PubMed Web of Science ®Google Scholar
• Kirby I, Davison E, Beavil AJ, et al. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol. 2000;74(6):2804. doi:10.1128/JVI.74.6.2804-2813.200010684297
   PubMed Web of Science ®Google Scholar
• Reeh M, Bockhorn M, Görgens D, et al. Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109:1848. doi:10.1038/bjc.2013.62324022195
   PubMed Web of Science ®Google Scholar
• Küster K, Koschel A, Rohwer N, Fischer A, Wiedenmann B, Anders M. Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1α. Cancer Gene Ther. 2009;17:141. doi:10.1038/cgt.2009.4919590529
   PubMed Web of Science ®Google Scholar
• Wu PC, Wang Q, Dong ZM, et al. Expression of coxsackie and adenovirus receptor distinguishes transitional cancer states in therapy-induced cellular senescence. Cell Death Dis. 2010;1:e70. doi:10.1038/cddis.2010.4721364674
   PubMed Web of Science ®Google Scholar
• Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003;40(2):109–123. doi:10.1016/s0161-5890(03)00112-312914817
   PubMed Web of Science ®Google Scholar
• Do M-H, To PK, Cho Y-S, et al. Targeting CD46 enhances anti-tumoral activity of adenovirus type 5 for bladder cancer. Int J Mol Sci. 2018;19(9):2694. doi:10.3390/ijms19092694
   Web of Science ®Google Scholar
• Lenman A, Liaci AM, Liu Y, et al. Polysialic acid is a cellular receptor for human adenovirus 52. Proc Natl Acad Sci. 2018;115(18):E4264. doi:10.1073/pnas.171690011529674446
   PubMed Web of Science ®Google Scholar
• Petridis AK, Wedderkopp H, Hugo HH, Maximilian Mehdorn H. Polysialic acid overexpression in malignant astrocytomas. Acta Neurochir (Wien). 2009;151(6):601–604. doi:10.1007/s00701-009-0324-319387537
   PubMed Web of Science ®Google Scholar
• Amoureux M-C, Coulibaly B, Chinot O, et al. Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer. 2010;10(1):91. doi:10.1186/1471-2407-10-66320219118
   PubMed Web of Science ®Google Scholar
• Suzuki M, Suzuki M, Nakayama J, et al. Polysialic acid facilitates tumor invasion by glioma cells. Glycobiology. 2005;15(9):887–894. doi:10.1093/glycob/cwi07115872150
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2004;23(1):515–548. doi:10.1146/annurev.immunol.23.021704.115611
   Web of Science ®Google Scholar
• Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel DT. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology. 2004;322(2):349–359. doi:10.1016/j.virol.2004.02.01615110532
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616–629. doi:10.1016/j.ymthe.2004.07.01315451446
   PubMed Web of Science ®Google Scholar
• Wang H, Li Z-Y, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2010;17:96. doi:10.1038/nm.227021151137
   PubMed Web of Science ®Google Scholar
• Chitaev NA, Troyanovsky SM. Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J Cell Biol. 1997;138(1):193. doi:10.1083/jcb.138.1.1939214392
   PubMed Web of Science ®Google Scholar
• S-E-H S, Trinnaman B, Martin S, Major S, Hutchinson J, Magee AI. Molecular interactions between desmosomal cadherins. Biochem J. 2002;362(2):317. doi:10.1042/bj362031711853539
   PubMed Web of Science ®Google Scholar
• Harrison OJ, Brasch J, Lasso G, et al. Structural basis of adhesive binding by desmocollins and desmogleins. Proc Natl Acad Sci. 2016;113(26):7160. doi:10.1073/pnas.160627211327298358
   PubMed Web of Science ®Google Scholar
• Biedermann K, Vogelsang H, Becker I, et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol. 2005;207(2):199–206. doi:10.1002/path.182116025435
   PubMed Web of Science ®Google Scholar
• Schmitt CJ, Franke WW, Goerdt S, Falkowska-Hansen B, Rickelt S, Peitsch WK. Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein. J Investig Dermatol. 2007;127(9):2191–2206. doi:10.1038/sj.jid.570084917495963
   PubMed Web of Science ®Google Scholar
• Abbod MF, Hamdy FC, Linkens DA, Catto JWF. Predictive modeling in cancer: where systems biology meets the stock market. Expert Rev Anticancer Ther. 2009;9(7):867–870. doi:10.1586/era.09.4719589024
   PubMed Web of Science ®Google Scholar
• Cai F, Zhu Q, Miao Y, Shen S, Su X, Shi Y. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res Clin Oncol. 2017;143(1):59–69. doi:10.1007/s00432-016-2250-027629878
   PubMed Web of Science ®Google Scholar
• Vassal-Stermann E, Effantin G, Zubieta C, et al. CryoEM structure of adenovirus type 3 fibre with desmoglein 2 shows an unusual mode of receptor engagement. Nat Commun. 2019;10(1):1181. doi:10.1038/s41467-019-09220-y30862836
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309–319. doi:10.1016/0092-8674(93)90231-E8477447
   PubMed Web of Science ®Google Scholar
• Chiu CY, Mathias P, Nemerow GR, Stewart PL. Structure of adenovirus complexed with its internalization receptor, alphavbeta5 integrin. J Virol. 1999;73(8):6759–6768.10400774
   PubMed Web of Science ®Google Scholar
• Veesler D, Cupelli K, Burger M, Gräber P, Stehle T, Johnson JE. Single-particle EM reveals plasticity of interactions between the adenovirus penton base and integrin αVβ₃. Proc Natl Acad Sci. 2014;111(24):8815.24889614
   PubMed Web of Science ®Google Scholar
• Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol. 1993;67(9):5198.8350395
   PubMed Web of Science ®Google Scholar
• Freimuth P. A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. J Virol. 1996;70(6):4081.8648746
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72(12):9706–9713.9811704
   PubMed Web of Science ®Google Scholar
• Millward S, Graham AF. Structural studies on reovirus: discontinuities in the genome. Proc Natl Acad Sci U S A. 1970;65(2):422–429. doi:10.1073/pnas.65.2.4224313198
   PubMedGoogle Scholar
• Loh PC, Shatkin AJ. Structural proteins of reoviruses. J Virol. 1968;2(11):1353.4973572
   PubMed Web of Science ®Google Scholar
• Chappell JD, Prota AE, Dermody TS, Stehle T. Crystal structure of reovirus attachment protein σ1 reveals evolutionary relationship to adenovirus fiber. Embo J. 2002;21(1–2):1. doi:10.1093/emboj/21.1.111782420
   PubMed Web of Science ®Google Scholar
• Kirchner E, Guglielmi KM, Strauss HM, Dermody TS, Stehle T. Structure of reovirus σ1 in complex with its receptor junctional adhesion molecule-a. PLoS Pathog. 2008;4(12):e1000235. doi:10.1371/journal.ppat.100023519079583
   PubMed Web of Science ®Google Scholar
• Reiter DM, Frierson JM, Halvorson EE, Kobayashi T, Dermody TS, Stehle T. Crystal structure of reovirus attachment protein σ1 in complex with sialylated oligosaccharides. PLoS Pathog. 2011;7(8):e1002166. doi:10.1371/journal.ppat.100216621829363
   PubMed Web of Science ®Google Scholar
• Naik MU, Naik TU, Suckow AT, Duncan MK, Naik UP. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res. 2008;68(7):2194. doi:10.1158/0008-5472.CAN-07-305718381425
   PubMed Web of Science ®Google Scholar
• Phillips MB, Stuart JD, Stewart RMR, Berry JTL, Mainou BA, Boehme KW. Current understanding of reovirus oncolysis mechanisms. Oncolytic Virotherapy. 2018. doi:10.2147/OV.S143808
   Web of Science ®Google Scholar
• Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010;28(5):641–649. doi:10.1007/s10637-009-9279-819572105
   PubMed Web of Science ®Google Scholar
• Morris DG, Feng X, DiFrancesco LM, et al. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs. 2013;31(3):696–706. doi:10.1007/s10637-012-9865-z22886613
   PubMed Web of Science ®Google Scholar
• Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127–7137.18981012
   PubMed Web of Science ®Google Scholar
• Noonan AM, Farren MR, Geyer SM, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther. 2016;24(6):1150–1158. doi:10.1038/mt.2016.6627039845
   PubMed Web of Science ®Google Scholar
• Comins C, Spicer J, Protheroe A, et al. REO-10: a phase i study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010;16(22):5564. doi:10.1158/1078-0432.CCR-10-061320926400
   PubMed Web of Science ®Google Scholar
• Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovirus, the cause of erythema infectiosum (FIFTH DISEASE)? Lancet. 1983;321(8338):1378. doi:10.1016/S0140-6736(83)92152-9
   Google Scholar
• Agbandje M, Kajigaya S, McKenna R, Young NS, Rossmann MG. The structure of human parvovirus B19 at 8 Å; resolution. Virology. 1994;203(1):106–115. doi:10.1006/viro.1994.14608030266
   PubMed Web of Science ®Google Scholar
• Marchini A, Bonifati S, Scott EM, Angelova AL, Rommelaere J. Oncolytic parvoviruses: from basic virology to clinical applications. Virol J. 2015;12:6. doi:10.1186/s12985-014-0223-y25630937
   PubMed Web of Science ®Google Scholar
• Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262(5130):114. doi:10.1126/science.82111178211117
   PubMed Web of Science ®Google Scholar
• Weigel-Kelley KA, Yoder MC, Srivastava A. α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entry. Blood. 2003;102(12):3927. doi:10.1182/blood-2003-05-152212907437
   PubMed Web of Science ®Google Scholar
• Roman J, Ritzenthaler JD, Roser-Page S, Sun X, Han S. alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol. 2010;43(6):684–691. doi:10.1165/rcmb.2009-0375OC20081050
   PubMed Web of Science ®Google Scholar
• Allaume X, El-Andaloussi N, Leuchs B, et al. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J Virol. 2012;86(7):3452. doi:10.1128/JVI.06208-1122258256
   PubMed Web of Science ®Google Scholar
• Hafenstein S, Palermo LM, Kostyuchenko VA, et al. Asymmetric binding of transferrin receptor to parvovirus capsids. Proc Natl Acad Sci. 2007;104(16):6585. doi:10.1073/pnas.070157410417420467
   PubMed Web of Science ®Google Scholar
• Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8(6):916–931.30034931
   PubMed Web of Science ®Google Scholar
• Sin J, Mangale V, Thienphrapa W, Gottlieb RA, Feuer R. Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology. 2015;484:288–304. doi:10.1016/j.virol.2015.06.00626142496
   PubMed Web of Science ®Google Scholar
• Oberste MS, Maher K, Pallansch MA. Molecular phylogeny and proposed classification of the simian picornaviruses. J Virol. 2002;76(3):1244. doi:10.1128/JVI.76.3.1244-1251.200211773400
   PubMed Web of Science ®Google Scholar
• Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229(4720):1358. doi:10.1126/science.229.4718.1038-a2994218
   PubMed Web of Science ®Google Scholar
• Xu S-J, Yang H, Yao X-J, et al. Complete genome sequences of four coxsackievirus A16 strains isolated from four children with severe hand, foot, and mouth disease. Genome Announc. 2017;5(31):e00760–e00717. doi:10.1128/genomeA.00760-1728774989
   PubMedGoogle Scholar
• Zhu L, Sun Y, Fan J, et al. Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating. Nat Commun. 2018;9(1):4985. doi:10.1038/s41467-018-07531-030478256
   PubMed Web of Science ®Google Scholar
• Hogle JM. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol. 2002;56(1):677–702. doi:10.1146/annurev.micro.56.012302.16075712142481
   PubMed Web of Science ®Google Scholar
• Bostina M, Levy H, Filman DJ, Hogle JM. Poliovirus RNA is released from the capsid near a twofold symmetry axis. J Virol. 2011;85(2):776. doi:10.1128/JVI.00531-1020980499
   PubMed Web of Science ®Google Scholar
• Strauss M, Levy HC, Bostina M, Filman DJ, Hogle JM. RNA transfer from poliovirus 135S particles across membranes is mediated by long umbilical connectors. J Virol. 2013;87(7):3903. doi:10.1128/JVI.03209-1223365424
   PubMed Web of Science ®Google Scholar
• Lyu K, Ding J, Han J-F, et al. Human enterovirus 71 uncoating captured at atomic resolution. J Virol. 2014;88(6):3114. doi:10.1128/JVI.03029-1324352461
   PubMed Web of Science ®Google Scholar
• He Y, Chipman PR, Howitt J, et al. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol. 2001;8:874. doi:10.1038/nsb1001-87411573093
   PubMedGoogle Scholar
• Martino TA, Petric M, Weingartl H, et al. The Coxsackie-Adenovirus Receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology. 2000;271(1):99–108. doi:10.1006/viro.2000.032410814575
   PubMed Web of Science ®Google Scholar
• Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol. 1996;70(11):7811.8892902
   PubMed Web of Science ®Google Scholar
• Yoder JD, Cifuente JO, Pan J, Bergelson JM, Hafenstein S. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with Decay-Accelerating Factor (DAF) provide a new footprint of DAF on the virus surface. J Virol. 2012;86(23):12571. doi:10.1128/JVI.01592-1222973031
   PubMed Web of Science ®Google Scholar
• Goodfellow IG, Evans DJ, Blom AM, et al. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol. 2005;79(18):12016. doi:10.1128/JVI.79.20.12905-12913.200516140777
   PubMed Web of Science ®Google Scholar
• Xiao C, Bator-Kelly CM, Rieder E, et al. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure. 2005;13(7):1019–1033. doi:10.1016/j.str.2005.04.01116004874
   PubMed Web of Science ®Google Scholar
• Baggen J, Hurdiss DL, Zocher G, et al. Role of enhanced receptor engagement in the evolution of a pandemic acute hemorrhagic conjunctivitis virus. Proc Natl Acad Sci. 2018;115(2):397. doi:10.1073/pnas.171328411529284752
   PubMed Web of Science ®Google Scholar
• Shafren DR. Viral cell entry induced by cross-linked decay-accelerating factor. J Virol. 1998;72(11):9407.9765499
   PubMed Web of Science ®Google Scholar
• Tsai S-T, Wang P-J, Liou N-J, Lin P-S, Chen C-H, Chang W-C. ICAM1 is a potential cancer stem cell marker of esophageal squamous cell carcinoma. PLoS One. 2015;10(11):e0142834. doi:10.1371/journal.pone.014283426571024
   PubMed Web of Science ®Google Scholar
• Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN. The intercellular cell adhesion molecule-1 (ICAM-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014;34(9):4665–4672.25202042
   PubMed Web of Science ®Google Scholar
• Benedicto A, Romayor I, Arteta B. Role of liver ICAM-1 in metastasis. Oncol Lett. 2017;14(4):3883–3892.28943897
   PubMed Web of Science ®Google Scholar
• Inoue T, Yamakawa M, Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol Pathol. 2002;55(3):193.12032231
   PubMedGoogle Scholar
• Nakagawa M, Mizuno M, Kawada M, et al. Polymorphic expression of decay-accelerating factor in human colorectal cancer. J Gastroenterol Hepatol. 2001;16(2):184–189.11207899
   PubMed Web of Science ®Google Scholar
• Bella J, Kolatkar PR, Marlor CW, Greve JM, Rossmann MG. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc Natl Acad Sci U S A. 1998;95(8):4140–4145.9539703
   PubMed Web of Science ®Google Scholar
• Au GG, Lincz LF, Enno A, Shafren DR. Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007;137(2):133–141.17391493
   PubMed Web of Science ®Google Scholar
• Skelding KA, Barry RD, Shafren DR. Enhanced oncolysis mediated by coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs. 2012;30(2):568–581.21170760
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72(10):2609–2621.22461509
   PubMed Web of Science ®Google Scholar
• Melnick JL. Current status of poliovirus infections. Clin Microbiol Rev. 1996;9(3):293.8809461
   PubMed Web of Science ®Google Scholar
• Yakovenko ML, Cherkasova EA, Rezapkin GV, et al. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J Virol. 2006;80(6):2641.16501074
   PubMed Web of Science ®Google Scholar
• Jiang P, Liu Y, Ma H-C, Paul AV, Wimmer E. Picornavirus Morphogenesis. Microbiol Mol Biol Rev. 2014;78(3):418.25184560
   PubMed Web of Science ®Google Scholar
• Miller ST, Hogle JM, Filman DJ. Ab initio phasing of high-symmetry macromolecular complexes: successful phasing of authentic poliovirus data to 3.0 Å resolution11Edited by I. A. Wilson. J Mol Biol. 2001;307(2):499–512.11254378
   PubMed Web of Science ®Google Scholar
• He Y, Mueller S, Chipman PR, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77(8):4827.12663789
   PubMed Web of Science ®Google Scholar
• Zhang P, Mueller S, Morais MC, et al. Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses. Proc Natl Acad Sci. 2008;105(47):18284.19011098
   PubMed Web of Science ®Google Scholar
• Strauss M, Filman DJ, Belnap DM, Cheng N, Noel RT, Hogle JM. Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry. J Virol. 2015;89(8):4143.25631086
   PubMed Web of Science ®Google Scholar
• He Y, Bowman VD, Mueller S, et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci. 2000;97(1):79.10618374
   PubMed Web of Science ®Google Scholar
• Butan C, Filman DJ, Hogle JM. Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J Virol. 2014;88(3):1758.24257617
   PubMed Web of Science ®Google Scholar
• Levy HC, Bostina M, Filman DJ, Hogle JM. Catching a virus in the act of RNA release: a novel poliovirus uncoating intermediate characterized by cryo-electron microscopy. J Virol. 2010;84(9):4426.20181687
   PubMed Web of Science ®Google Scholar
• Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017;108(10):1934–1938.28730595
   PubMed Web of Science ®Google Scholar
• Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56(5):855–865.2538245
   PubMed Web of Science ®Google Scholar
• Chadéneau C, LeCabellec M, LeMoullac B, Meflah K, Denis MG. Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas. Int J Cancer. 1996;68(6):817–821.8980189
   PubMed Web of Science ®Google Scholar
• Chadéneau C, LeMoullac B, Denis MG. A novel member of the immunoglobulin gene superfamily expressed in rat carcinoma cell lines. J Biol Chem. 1994;269(22):15601–15605.8195207
   PubMed Web of Science ®Google Scholar
• Lim Y-P, Fowler LC, Hixson DC, Wehbe T, Thompson NL. TuAg.1 is the liver isoform of the rat colon tumor-associated antigen pE4 and a member of the immunoglobulin-like supergene family. Cancer Res. 1996;56(17):3934.8752160
   PubMed Web of Science ®Google Scholar
• Erickson BM, Thompson NL, Hixson DC. Tightly regulated induction of the adhesion molecule necl-5/CD155 during rat liver regeneration and acute liver injury. Hepatology. 2006;43(2):325–334.16440345
   PubMed Web of Science ®Google Scholar
• Bodian D. Histopathologic basis of clinical findings in poliomyelitis. Am J Med. 1949;6(5):563–578.18119382
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–161.29943666
   PubMed Web of Science ®Google Scholar
• Hales LM, Knowles NJ, Reddy PS, Xu L, Hay C, Hallenbeck PL. Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus. J Gen Virol. 2008;89(5):1265–1275.18420805
   PubMed Web of Science ®Google Scholar
• Xu W, Hole K, Goolia M, et al. Genome wide analysis of the evolution of senecavirus A from swine clinical material and assembly yard environmental samples. PLoS One. 2017;12(5):e0176964.28475630
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Z, Yang F, et al. Review of seneca valley virus: a call for increased surveillance and research. Front Microbiol. 2018;9:940.29867849
   PubMed Web of Science ®Google Scholar
• Leme RA, Alfieri AF, Alfieri AA. Update on senecavirus infection in pigs. Viruses. 2017;9(7):170.
   PubMed Web of Science ®Google Scholar
• Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. J Clin Invest. 2017;127(8):2957–2967.28650343
   PubMed Web of Science ®Google Scholar
• Bachran C, Leppla HS. Tumor targeting and drug delivery by anthrax toxin. Toxins. 2016;8(7):pii: E197.
   Web of Science ®Google Scholar
• Cullen M, Seaman S, Chaudhary A, et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res. 2009;69(15):6021.19622764
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Hilton Mary B, Seaman S, et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell. 2012;21(2):212–226.22340594
   PubMed Web of Science ®Google Scholar
• Jayawardena N, Burga LN, Easingwood RA, Takizawa Y, Wolf M, Bostina M. Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus. Proc Natl Acad Sci. 2018;115(46):E10934.30381454
   PubMed Web of Science ®Google Scholar
• Strauss M, Jayawardena N, Sun E, Easingwood RA, Burga LN, Bostina M. Cryo-electron microscopy structure of Seneca Valley Virus procapsid. J Virol. 2018;92(6):e01927–e01917.29263256
   PubMed Web of Science ®Google Scholar
• Burke MJ. Oncolytic Seneca Valley Virus: past perspectives and future directions. Oncolytic Virotherapy. 2016;5:81–89.27660749
   PubMed Web of Science ®Google Scholar
• Reddy PS, Burroughs KD, Hales LM, et al. Seneca Valley Virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007;99(21):1623–1633.17971529
   PubMedGoogle Scholar
• Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17(4):888–895.21304001
   PubMed Web of Science ®Google Scholar
• Bender FC, Whitbeck JC, Lou H, Cohen GH, Eisenberg RJ. Herpes Simplex Virus Glycoprotein B Binds to Cell Surfaces Independently of Heparan Sulfate and Blocks Virus Entry. J Virol. 2005;79(18):11588–11597.16140736
   PubMed Web of Science ®Google Scholar